DENVER, CO / ACCESSWIRE / January 15, 2019 / Medicine Man Technologies, a consulting, IP licensing and products company in the cannabis industry, has signed binding term sheets and conditions for acquisition of MedPharm Holdings LLC, an intellectual property development and holding company focused on cannabis research and product/brand development.
MedPharm Holdings LLC provides extraction expertise, cannabis pharmaceutical-grade dosage forms using current “Good Manufacturing Practices” that include pre-formulation; formulation development; commercial manufacturing; analytical method development and validation; and routine quality control analysis and stability studies. MedPharm’s capabilities also allow for in-depth analysis to include clinical studies. MedPharm’s popular brands include: Aliviar, a medically focused line with a proprietary blend of cannabinoids, terpenes, niosomes, essential oils and other excipients; become, a pure cannabis concentrate marketed to the female demographic and BATCH, high-quality extracts for the connoisseur.
MedPharm Holdings LLC has two licensees. The first is MX, LLC in Colorado, an extraction and marijuana-infused products company, which holds the only Colorado state cannabis research license. The second is MedPharm Iowa, a vertically integrated medical marijuana company. MedPharm Holdings LLC also has a pending application for a federal research Bulk Manufacturer license to provide cannabis and cannabis dosage forms for research purposes.
MedPharm Holdings LLC is currently solidifying an international expansion in South America and evaluating opportunities in other continents.
:This planned acquisition of MedPharm Holdings LLC brings world-class processing, research and pharmaceutical-grade products to the Medicine Man Technologies’ portfolio," Andy Williams, Medicine Man Technologies CEO, said. "This is a significant step in becoming a dominant global operator, filling a key gap in our current products and services. We have had clients in 17 states and seven countries, this highly scalable product line allows us to leverage those existing relationships worldwide.
The acquisition of MedPharm Holdings, LLC is expected to close sometime in the first quarter of 2019 pending completion of due diligence.